Zobrazeno 1 - 10
of 316
pro vyhledávání: '"Catherine C. Smith"'
Autor:
Astrid Wintering, Anna Hecht, Julia Meyer, Eric B. Wong, Juwita Hübner, Sydney Abelson, Kira Feldman, Vanessa E. Kennedy, Cheryl A.C. Peretz, Deborah L. French, Jean Ann Maguire, Chintan Jobaliya, Marta Rojas Vasquez, Sunil Desai, Robin Dulman, Eneida Nemecek, Hilary Haines, Mahmoud Hammad, Alaa El Haddad, Scott C. Kogan, Zied Abdullaev, Farid F. Chehab, Sarah K. Tasian, Catherine C. Smith, Mignon L. Loh, Elliot Stieglitz
Publikováno v:
Haematologica, Vol 999, Iss 1 (2023)
Mutations in five canonical Ras pathway genes (NF1, NRAS, KRAS, PTPN11 and CBL) are detected in nearly 90% of patients with juvenile myelomonocytic leukemia (JMML), a frequently fatal malignant neoplasm of early childhood. In this report, we describe
Externí odkaz:
https://doaj.org/article/6b7a3df1a4054f309e85875af70a1441
Autor:
Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C. Smith, Mark J. Levis, Stephen Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je-Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Jessica K. Altman
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-9 (2022)
Abstract The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemoth
Externí odkaz:
https://doaj.org/article/177517e470014866a24e2133dc705fd7
Autor:
Benjamin Demaree, Cyrille L. Delley, Harish N. Vasudevan, Cheryl A. C. Peretz, David Ruff, Catherine C. Smith, Adam R. Abate
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
It is currently difficult to map DNA variants and surface phenotypes in the same cells, preventing direct linkage of phenotype and genotype. Here the authors report DAb-seq for simultaneous capture of DNA genotype and cell surface phenotype from sing
Externí odkaz:
https://doaj.org/article/dfb07e6143424db5a2a57dd7798d784c
Autor:
Thai Hoa Tran, Jonathan V. Nguyen, Adrian Stecula, Jon Akutagawa, Anthony V. Moorman, Benjamin S. Braun, Andrej Sali, Charles G. Mullighan, Neil P. Shah, Yunfeng Dai, Meenakshi Devidas, Kathryn G. Roberts, Catherine C. Smith, Mignon L. Loh
Publikováno v:
Haematologica, Vol 106, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/6b4cc17e613943ff9b4b6ed26ceaa218
Autor:
Vanessa E. Kennedy, Catherine C. Smith
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts. Mutations in FLT3 are the most common genetic alteration in AML, identified in approximately one third of newly diagnosed patients. FLT3 internal tandem duplic
Externí odkaz:
https://doaj.org/article/c9e1af1bb9e94271a048d0fc08336bf9
Autor:
Anindya Chatterjee, Joydeep Ghosh, Baskar Ramdas, Raghuveer Singh Mali, Holly Martin, Michihiro Kobayashi, Sasidhar Vemula, Victor H. Canela, Emily R. Waskow, Valeria Visconte, Ramon V. Tiu, Catherine C. Smith, Neil Shah, Kevin D. Bunting, H. Scott Boswell, Yan Liu, Rebecca J. Chan, Reuben Kapur
Publikováno v:
Cell Reports, Vol 9, Iss 4, Pp 1333-1348 (2014)
Oncogenic mutations of FLT3 and KIT receptors are associated with poor survival in patients with acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs), and currently available drugs are largely ineffective. Although Stat5 has been impl
Externí odkaz:
https://doaj.org/article/3fb0e4f417624b859de3a4859396cf8a
Autor:
Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C. Smith, Gary Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Deanna Brackman, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman
Publikováno v:
Journal of Clinical Oncology. 40:4048-4059
PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated ( FLT3 mut) acute myeloid leukemia (AML) but seldom reduces FLT3 mut burden or induces sustained efficacy. Gilteritinib c
Autor:
Cheryl A. C. Peretz, Vanessa E. Kennedy, Anushka Walia, Cyrille L. Delley, Andrew Koh, Elaine Tran, Iain C. Clark, Corey E. Hayford, Chris D’Amato, Yi Xue, Kristina M. Fontanez, Ritu Roy, Aaron C. Logan, Alexander E. Perl, Adam Abate, Adam Olshen, Catherine C. Smith
Publikováno v:
bioRxiv
Mixed phenotype acute leukemia (MPAL) is a leukemia whose biologic drivers are poorly understood, therapeutic strategy remains unclear, and prognosis is poor. We performed multiomic single cell (SC) profiling of 14 newly diagnosed adult MPAL patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329a4b6352dbc716d347cb4555c49934
https://europepmc.org/articles/PMC10245585/
https://europepmc.org/articles/PMC10245585/
Autor:
Alexander E. Perl, Catherine C. Smith, Martin Carroll, Neil P. Shah, Selina M. Luger, Aaron C. Logan, Safoora Deihimi, Lisa H.F. McGary, Cheryl A.C. Peretz, RosaAnna DeFilippis, Elisabeth A. Lasater, Saurabh Asthana, Christopher D. Watt, Robert Durruthy-Durruthy, Maurizio Pellegrino, Dennis J. Eastburn, Jennifer J.D. Morrissette, Eunice S. Wang, Jonathan Canaani, Timothy Ferng, Christine M. McMahon
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9342e80b4dcae04c4e27e5d1a7598d23
https://doi.org/10.1158/2159-8290.c.6548240.v1
https://doi.org/10.1158/2159-8290.c.6548240.v1
Autor:
Neil P. Shah, Gideon Bollag, Brian L. West, Gaston Habets, Henry H. Hsu, Mai H. Le, Prabha N. Ibrahim, Wayne Spevak, Jiazhong Zhang, Bernice Matusow, Elizabeth A. Burton, Ben Powell, Heidi Carias, Garson Tsang, Rafe Shellooe, Andrew Kasarskis, Alexander Perl, Robert Sebra, Ali Bashir, Matthew Pendleton, Lauren E. Damon, Evan Massi, Ying Zhang, Elisabeth A. Lasater, Kimberly C. Lin, Chao Zhang, Catherine C. Smith
Supplementary Table 1. Crystallographic Data and Refinement statistics. Supplementary Table 2. Comparing Target Inhibition by Quizartinib and PLX3397 in Engineered Ba/F3 cells Expressing FLT3-ITD, FLT3-ITD/F691L and FLT3-ITD/D835Y. Supplementary Tabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3238bc9253c505ce861afdefa65ccf
https://doi.org/10.1158/2159-8290.22531562.v1
https://doi.org/10.1158/2159-8290.22531562.v1